CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishItalian pharmaceutical policy has recently moved towards a “two lanes” approach, with regulation differing according to a drug’s patent status. This study analyses the Italian regulatory framework, focusing on policies related to “off-patent” drugs. Three main regulatory innovations have been examined: (i) generics, introduced in Italy for the first time in 1996; (ii) the reference pricing (RP) scheme, under which consumers pay part of the cost of high-priced products; (iii) pharmacists’ right of substitution, supported by a regressive margins system. The recent reforms are already producing some worthwhile results, at least in terms of competitive pressure on the (few) substances that run out of patent protection. However, further intervention could be required to achieve long-term sustainability.
PRODOTTO NON ANCORA VALIDATO
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Italian Pharmaceutical Policy: Towards a Structural Change? | |
| Data di pubblicazione: | 2005 | |
| Autori: | ||
| Autori: | Ghislandi, Simone; Krulikova, I; Garattini, L. | |
| Rivista: | HEALTH POLICY | |
| Abstract: | Italian pharmaceutical policy has recently moved towards a “two lanes” approach, with regulation differing according to a drug’s patent status. This study analyses the Italian regulatory framework, focusing on policies related to “off-patent” drugs. Three main regulatory innovations have been examined: (i) generics, introduced in Italy for the first time in 1996; (ii) the reference pricing (RP) scheme, under which consumers pay part of the cost of high-priced products; (iii) pharmacists’ right of substitution, supported by a regressive margins system. The recent reforms are already producing some worthwhile results, at least in terms of competitive pressure on the (few) substances that run out of patent protection. However, further intervention could be required to achieve long-term sustainability. | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.healthpol.2004.02.012 | |
| Appare nelle tipologie: | 01 - Article in academic journal / Articolo su rivista scientifica |
File in questo prodotto:
http://hdl.handle.net/11565/40124
Copyright © 2021